Cyclic guanosine monophosphate (cGMP) in penile vascular smooth muscle cells (VSMC) plays a key role in promoting penile erection. Phosphodiesterase-5 (PDE5) in VSMC breaks down cGMP to counter this effect. Sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis), treatments for erectile dysfunction, inhibit PDE5 action. Many men with erectile dysfunction have improved erectile function after plasma inhibitor concentration falls below therapeutic levels. Maximum effect plus onset and duration of action of inhibitor determines its efficacy. The rate and extent of cellular drug accumulation and efflux of drug from smooth muscle cells plus persistence of drug effects in these cell impact these parameters. We propose possible molecular mechanisms that could account for prolonged action of PDE5 inhibitors including (1) persistence of biochemical effects after inhibitor is cleared from cells, and (2) retention of drug in VSMC beyond plasma clearance.
Introduction
The central role of cyclic guanosine monophosphate (cGMP) signaling in the erectogenic response of penile tissues to sexual stimuli is now well established. 1, 2 Nitric oxide (NO) released from both nonadrenergic noncholinergic nerve terminals and endothelial cells of the penis activates a NOsensitive guanylyl cyclase to increase conversion of GTP to cGMP ( Figure 1 ). Cyclic GMP binds with high affinity to cGMP-dependent protein kinase (PKG) and activates this enzyme to cause phosphorylation of numerous cellular proteins that are involved in modulating the level of cellular calcium and calcium sensitivity of calcium-regulated pathways. [3] [4] [5] The consequences of this effect, that is, cGMP activation of PKG activity, are central to the contractile state of penile vascular smooth muscle cells (VSMC) and the erectile response to sexual stimuli ( Figure 1 ). 1, 6, 7 Phosphodiesterase-5 (PDE5), which is abundant in VSMC, specifically breaks down cGMP to the inactive 5 0 -GMP at its catalytic site and also binds cGMP at nonhydrolytic allosteric sites in its regulatory domain; [8] [9] [10] cGMP binding to the allosteric sites increases activity of the catalytic site. [11] [12] [13] The cellular cGMP level in corpus cavernosum is primarily dictated by the balance between the rate of cGMP synthesis by guanylyl cyclases and cGMP breakdown by PDE5. Under healthy physiological conditions, cGMP elevation in penile tissues in response to sexual stimulation is sufficient to cause selective vasodilatation of the penile vasculature and engorgement of the organ. This pathway can be compromised in a number of ways including decreased blood flow due to structural and functional deterioration of the peripheral vascular bed and/or nerves, insufficient production of NO by neurons and/or endothelium, excessive breakdown of cGMP by PDE5, decreased compliance of the VSMC and penile connective tissue or a combination of these processes. As can be seen in Figure 1 , deficiencies in several other sites of the signaling pathway are also possible. In some of these scenarios, cGMP elevation in the VSMC may not be adequate to provide for a sufficient degree of penile tumescence thereby resulting in erectile dysfunction (ED). However, inhibition of PDE5 activity would favor greater accumulation of cGMP and facilitate the erectile response in many of these conditions. 7, [14] [15] [16] Use of PDE5 inhibitors to treat disease PDE5 is the target of three potent PDE5-selective inhibitors (sildenafil, (Viagra), vardenafil (Levitra) and tadalafil (Cialis)), which are commercially available in many countries as oral treatment for ED. 17 Sildenafil (marketed as Revatio) has also been approved in the United States and Europe as an oral treatment of pulmonary arterial hypertension; the three drugs are currently being investigated for potential use in treatment of a number of other medical problems including cardiac hypertrophy associated with heart failure, Raynaud's disease, premature ejaculation, priapism, Peyronie's disease, recovery from stroke, cardiac reperfusion injury, intermittent claudication, benign prostate syndrome and other lower urinary tract symptoms, overactive bladder, female sexual dysfunction, cognitive functions and adjustment of the circadian rhythm. 18 Increased use of these drugs in a number of medical settings, and in some instances use of a different dosing regimen, may mandate closer consideration of the pharmacokinetics of these medications and characteristics reported by patients currently using the products. PDE5 inhibitors other than sildenafil, vardenafil and tadalafil have also either already been launched or are in clinical trials in world markets. 19 The pharmacokinetics of sildenafil, vardenafil and tadalafil have been well documented overall. The onset of action, maximum effect and duration of action of PDE5 inhibitors are among many pharmacokinetic factors that must be considered for optimal efficacy of the medications as well as ease and safety of use by patients. Among many such factors, the rate of accumulation, extent of accumulation and rate of efflux of drug in cells will impact these parameters. There are now numerous reports that many individuals who use PDE5 inhibitor medications experience an improvement in the erectile response long after the plasma level of the respective drug is below what is considered to be a therapeutic level. [20] [21] [22] [23] [24] In this report, we will discuss molecular mechanisms that could account for prolonged action of PDE5 inhibitors.
Sildenafil, vardenafil, and tadalafil have high inhibitory affinity (IC 50 ¼ 4, 0.1-0.4 and 2 nM, respectively) for the catalytic site of PDE5 compared to the B600-to 25 000-fold lower affinity of the natural substrate, cGMP (K m B2.5 mM). [25] [26] [27] [28] PDE5-selective inhibitors compete with cGMP for access to the catalytic site and are therefore known as 'competitive inhibitors'. 12, 28, 29 The three inhibitors do not interact with the nonhydrolytic allosteric cGMP-binding sites on PDE5 (Figure 1 ). 29 Prolonged action of PDE5 inhibitors in treatment of ED By all accounts, efficacy of action of sildenafil, vardenafil or tadalafil to enhance the erectile response appears to compare well. The time (T max ) required to reach maximum plasma concentration (C max ) and the time of onset of action vary slightly with tadalafil being slightly slower than sildenafil or vardenafil. However, the drugs differ substantially in the rate of clearance from plasma; t1 2 of plasma clearance is B4 h for sildenafil or vardenafil compared to 18 h for tadalafil. Effect of sildenafil or vardenafil in men is optimum at B0.5-1 h, which approximates the time of peak plasma concentration (C max ). Plasma concentration of these drugs wanes with t1 2 of B4-5 h so that plasma drug level would be low after 12 h (B13% of C max ). However, studies indicate that men still have facilitated erections 12 h after dosing. 20, 30, 31 17 The prolonged effectiveness of these medications adds flexibility to initiation of sexual activity for patients with ED and could reduce frequency of dosing. If this pattern applies to other tissues (for example, the pulmonary vasculature), it could mean that less frequent dosing regimens might be used to bring about the desired therapeutic goal. This could result in lower exposure of the patient to medication and cost savings for the therapy.
The time course of drug action is generally thought to closely correlate with plasma level of the drug. According to this model, clearance of a drug from plasma, exit of drug from the tissue and cessation of drug action in that tissue would essentially coincide. However, prolonged action of potent PDE5 inhibitors does not fit this model well. Several biochemical mechanisms might explain the apparently prolonged effect of PDE5 inhibitors. (1) If the inhibitor is cleared from tissue in parallel with its clearance from plasma, then the persistence of its biological effects must be due to prior exposure of the tissue to inhibitor perhaps in combination with persistent activation of the cGMP-signaling pathway during the time of exposure (that is, cellular 'memory' of the cGMP-signaling experience). Moreover, if the drug has been cleared from the cell, PDE5 activity would be restored and cGMP level would be predicted to be near basal level ( Figure 2a) . (2) Alternatively, if drug is not cleared in parallel with clearance from plasma, that is, drug is retained (or sequestered) in VSMC of the corpus cavernosum and breakdown of cGMP by PDE5 remains largely blocked (Figure 2b ), a low level of other cGMPhydrolyzing PDEs present in these cells could lower cGMP somewhat. This would foster (1) sustained cGMP binding to allosteric cGMP-binding sites on PDE5 to enhance affinity for inhibitors, (2) sustained cGMP binding to PKG and activation of the cGMPsignaling pathway and (3) increased cellular cGMP that is not readily hydrolyzed. In this latter scenario, cellular concentrations of PDE5 inhibitor and cGMP would be elevated to some extent, which would result from specific sequestration of each of these ligands, that is, inhibitor bound tightly to the PDE5 catalytic site and cGMP bound tightly to allosteric cGMP-binding sites in PKG and PDE5. These possible explanations for prolonged effects of PDE5 inhibitors on the erectile response will be considered herein. These hypotheses are based on established molecular mechanisms known to be associated with PDE5 and PKG although the considerations do not exclude other mechanisms.
Persistent consequences of activation of the cGMP-signaling pathway
The possibility of a 'memory' effect following exposure of tissue to PDE5 inhibitors either with or without concomitant elevation of cGMP will first be considered. Ordinarily, elevation of cGMP and activation of PKG set in motion a cascade of cellular events, and action of PDE5 counters this effect by hydrolyzing the nucleotide. In tissues that have been studied, evidence suggests that the action of PDEs accounts for the major portion of the capacity of the cell to reduce cyclic nucleotide levels. 32, 33 The presence of PDE5 inhibitors blocks action of PDE5 and enhances cGMP accumulation and cGMP signaling. It is not known if the level of cGMP achieved in the presence of PDE5 inhibitors is similar to that which occurs under physiological conditions or if cGMP accumulates to a much higher level. In porcine coronary artery smooth muscles, a threefold elevation of cGMP produces maximum relaxation. 34 PDE5 is the major cGMP-hydrolyzing PDE in corpus cavernosum 8 so that as long as PDE5 inhibitors are present, a significant cGMP level is likely to persist in this tissue even after the erection has subsided due to other influences. If so, PKG is likely to remain activated to some extent for several hours.
The long duration of the increased action of PKG described above could elicit effects not experienced under most physiological circumstances since PDE5 action in the absence of inhibitors would be predicted to quickly return cGMP and activity of PKG to near basal level. The effects of phosphorylation reactions mediated by PKG are generally thought to be rapidly counterbalanced by the action of phosphoprotein phosphatases. Even in the face of declining cGMP and decreased PKG activity, reversal of the effects of PKG phosphorylations may differ among the phosphoproteins; some may be rapidly dephosphorylated and returned to their original functional state, others may be protected against rapid dephosphorylation by their location in the cell or by being complexed with other proteins, thereby sustaining the original effect of increased cGMP. In fact, little is known about the true consequences and time courses of the action of either of these pathways. If activation of PKG and/or effects of PKGmediated phosphorylations are not fully reversed in a timely fashion (Figure 2a ), subsequent elevation of cGMP by erotic stimuli may produce a heightened erectile response even in the absence of PDE5 inhibitors. A prolonged effect of phosphorylation events on cellular protein function could occur by a number of mechanisms including (1) prolonged phosphorylation of target proteins in the cell perhaps due to slow dephosphorylation by phosphoprotein phosphatases, (2) structural changes such as conversion between forms that have different levels of activity, (3) alterations in protein levels due to alteration in gene expression, mRNA translation and/or stability, and/or protein turnover rate, (4) translocation of proteins between cellular compartments and (5) increased sensitivity to cGMP and/or the cGMP-signaling pathway. Figure 2 Potential processes that could contribute to persistence of the effects of activation of the cyclic guanosine monophosphate (cGMP)-signaling pathway in vascular smooth muscle cells (VSMC) in presence of phosphodiesterase-5 (PDE5) inhibitors. Following administration of PDE5 inhibitor and sexual stimulation, high cGMP level in the VSMC may be achieved and sustained for several hours because PDE5 breakdown of cGMP would be blocked. (a) If inhibitor is cleared from the cell in parallel with clearance from the plasma, PDE5 activity would be restored, cGMP would be lowered and protein kinase (PKG) activation would decline (as indicated by the white arrows). However, prolonged effects of PKG phosphorylation of proteins that occurred when the cGMP-signaling pathway was very active may persist. (b) If inhibitor is retained in the cell long after it has been largely cleared from plasma, PDE5 activity would continue to be blocked (indicated by the white arrow) and high level of cGMP resulting from earlier sexual stimulation would be preserved since PDE5 is the main cGMP-hydrolyzing PDE in penile tissue. Continued activation of PKG would sustain phosphorylation events mediated by this enzyme including phosphorylation of PDE5 (indicated by P) and PKG autophosphorylation indicated by P that renders both enzymes more sensitive to cGMP effects.
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PKG-mediated phosphorylation of PDE5 produces an apparent conformational change in the enzyme and increases affinity for cGMP at its allosteric sites and for inhibitors/cGMP at its catalytic site. 11, [35] [36] [37] Cyclic GMP-activated PKG undergoes autophosphorylation, which slightly elevates the enzyme's activity even in the absence of cGMP and increases its sensitivity to subsequent increases in cGMP (Figure 3) . [38] [39] [40] [41] Autophosphorylation also causes an apparent conformational change in the enzyme and promotes higher affinity for cGMP binding compared to unphospho-PKG, thereby retaining cGMP at the allosteric cGMP-binding sites; 38, 42 since the cGMP-binding allosteric sites of PKG are positively cooperative, 43 this would tend to 'prime' PKG for full activation by a subsequent small increase in cGMP. Some proteins that have been phosphorylated by PKG may subsequently be covalently modified by other posttranslational modifications such as oxidation, ubiquitination or phosphorylation by other kinases that could prolong or otherwise impact the consequences of cGMP signaling.
Changes in the level of proteins that are substrates for PKG could occur by numerous processes. PKGmediated phosphorylation targets transcription factors that regulate gene expression, 44, 45 which could alter levels of proteins downstream of PKG. In other instances, phosphorylation can target proteins for breakdown via the ubiquitination pathway. 46, 47 Cyclic GMP activation of PKG in some cells elicits translocation of the enzyme from the cytosol to specific subcellular locations and phosphorylation of target proteins within that compartment. 44, 45, [48] [49] [50] Activation of PKG has also been shown to elicit redistribution of certain proteins, for example, RhoA, 51 within the cell or insertion of proteins into membranes thereby altering function. 52, 53 Some cellular processes affected by PKG activity, for example, changes in the polymerization of fibrillar proteins or insertion of proteins into membranes may be slow to reverse. These are important considerations when applying pharmacological regimens that foster elevation of cGMP and which may be sustained for several hours or even days if the individual is chronically medicated. The consequences of short-term changes in the activity of the cGMP-signaling pathway may differ significantly from that of a more sustained activation and warrant careful investigation.
Retention of PDE5 inhibitors in VSMC after clearance from plasma
The possibility that PDE5 inhibitors may be retained in VSMC and promote improved erectile response even after they are cleared from the plasma is also plausible (Figures 2b and 4) . Sildenafil, vardenafil and tadalafil are not metabolized in the VSMC; for reversal of the effect of these medications in tissue, the drugs must dissociate from PDE5, diffuse through the cytosol to the plasma membrane, traverse the plasma membrane and be transported to the liver for modification and clearance by the action of cytochromes. Drugs such as these that have relatively short plasma half-lives, bind with high affinity to intracellular receptors such as PDE5, but are not degraded in the target cell, are in a somewhat unique class that has not been studied extensively. Unanticipated cellular pharmacokinetic characteristics that affect cellular clearance may apply to these drugs.
The entry and accumulation of PDE5 inhibitors in cells are expected to be impacted by the level of PDE5. Accordingly, cells that are abundant in PDE5 are predicted to selectively acquire and retain the inhibitor compared to cells with little or no PDE5 (Figures 4a-c) . Following absorption of the drugs into the blood stream, the inhibitor is transported to the VSMC surface by the systemic circulation. Initially, absence of the drug in the cytosol creates a large chemical gradient for the compound between the exterior and interior of the cell; this would facilitate drug entry into the cell (Figure 4a ). Since the inhibitors are bound with very high affinity to PDE5, it is predicted that as soon as an inhibitor enters the cell, it will almost instantaneously be bound by PDE5, that is, largely sequestered from the cytosol, and free inhibitor in the cytosol will remain (Figure 4a ). Furthermore, a significant portion of the inhibitor molecules that dissociate from PDE5 would likely rebind to the enzyme before leaving the cell. These factors would facilitate accumulation of inhibitor in the cell commensurate with cellular level of PDE5. According to this model, accumulation of inhibitor in the cell would be saturable and determined by concentration of intracellular PDE5. When all of the PDE5 catalytic sites are filled (saturated), concentration of free inhibitor in the cytosol would eventually approach that in plasma (Figure 4b ), but total inhibitor in the cell would be significantly impacted by the level of PDE5 in that cell so that total inhibitor in the cell ¼ inhibitor bound to PDE5 þ free inhibitor in the cytosol. The prolonged action of the commercialized PDE5 inhibitors reported in some patients is also predicted to result from the same processes, that is, the combined effects of (1) high level of PDE5 in VSMC and (2) high affinity of PDE5 for these inhibitors. The basal affinity of PDE5 for the inhibitors, which is intrinsically high (K D ¼ 0.1-4 nM), can increase further in response to elevation of cGMP as would occur with sexual stimulation 12 and/or prolonged exposure to the respective drugs. 54 As discussed below, this increased affinity is caused by allosteric binding of cGMP to PDE5, increased phosphorylation of the enzyme and prolonged perturbation of the catalytic site of the enzyme by elevated cGMP and inhibitor. 9, 11, 12, 55 Therefore, a few hours after ingestion of a PDE5 inhibitor either in the presence or absence of sexual arousal, plasma inhibitor concentration would be high and it is predicted that the catalytic site of PDE5 in VSMC would be saturated with inhibitor and that the affinity of PDE5 for the inhibitor would be significantly higher than in the basal state (Figure 4b ). This higher affinity binding would foster continued association of the inhibitor with PDE5 and retention of the inhibitor in the VSMC.
In simplest terms, 56, 57 VSMC can be considered to resemble dialysis bags containing both unbound and PDE5-bound inhibitors. As plasma inhibitor declines, free inhibitor in the cytosol of the cell would be expected to decline in parallel. However, the population of inhibitor molecules bound in a PDE5-inhibitor complex may decline more slowly ( Figures  4c and 5) because escape of the inhibitor from the cell is not exclusively dependent on the rate of diffusion of that molecule through the membrane to the plasma. Rather, PDE5 molecules may significantly interfere with inhibitor exit. Inhibitors are reversibly bound to PDE5 so that the complex is in a dynamic equilibrium, that is, the inhibitor is Figure 4a ) and increase affinity of the enzyme for inhibitor as indicated by the embedding of the inhibitor in the black oval. Favored interaction between inhibitor and PDE5 is indicated by the heavy arrows. In this situation, free inhibitors in the plasma and cytosol are equal. (c) Despite essential clearance of inhibitor from plasma surrounding the cell, significant amount of inhibitor remains bound to PDE5 inside the cell and loss of inhibitor from the cell is slowed.
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constantly dissociating from the enzyme at a certain rate (k off ) and being rebound at a certain rate (k on ) ( Figure 5 ). The ratio of k off to k on (called K D ) reflects the affinity of the enzyme for the inhibitor. With high-affinity inhibitors, association with PDE5 is favored in this equilibrium so that much of the inhibitor rebinds quickly after it dissociates from the enzyme. The high concentration of PDE5 would also foster rebinding of the inhibitor because the on-rate of inhibitor binding is affected by concentration of both inhibitor and PDE5. As some of the inhibitor escapes the cell and is removed from the vicinity of the cell by the circulation, there would be 'open' PDE5 catalytic sites so that not only would rebinding of the inhibitor occur with the same PDE5, but also other PDE5 molecules would be available to intercept and bind the inhibitor (Figure 5 ), thereby further impeding escape from the cell. Therefore, an inhibitor molecule would have a much higher probability of rebinding to free sites on PDE5 than of leaving the cell. Such a dissociation and reassociation scenario of the drug for PDE5 could potentially occur many times before clearance of the drug from the cytosol is achieved. This could result in concentration and retention, or 'trapping', of the drug in VSMC, thus extending its duration of action.
The effect of these processes to slow the t1 2 of inhibitor efflux from VSMC can be quantified by considering the concentration of PDE5 in cells along with the affinity of PDE5 for the inhibitor. The effect of PDE5 to slow inhibitor exit from the cell would be proportional to 1 þ P/K D , where P is the concentration of inhibitor-binding sites on PDE5 (PDE5 subunit concentration) and K D is the equilibrium dissociation constant of the PDE5-inhibitor complex. 56 Assuming that PDE5 is B5 Â 10 À7 M in VSMC 8 (unpublished data) and that K D of unphosphorylated PDE5 for vardenafil is 4 Â 10 À10 M, 12 intracellular binding of inhibitor to PDE5 would decrease the rate of efflux of this inhibitor by a factor ofB1500 compared to the rate of efflux in cells with no PDE5. This factor would be 41500 if the affinity of the PDE5 catalytic site for inhibitors such as vardenafil is increased by cellular events such as binding of cGMP to the PDE5 allosteric sites, phosphorylation of PDE5, prolonged exposure of the protein to inhibitor or other processes. While PDE5 has an intrinsically high affinity for sildenafil, vardenafil and tadalafil, modifications of the protein have been shown to further enhance affinity for some or all of these inhibitors, creating very high affinity binding ( Figure 6 ); these include cGMP binding to PDE5 allosteric sites and catalytic site, phosphorylation of the enzyme by PKG which is facilitated by either inhibitor binding to PDE5 catalytic site or cGMP binding to allosteric sites on PDE5, exposure of the enzyme to inhibitor for several hours or a combination of these effects. 9, [11] [12] [13] 35, 55 Because cGMP binding to allosteric cGMPbinding sites on PDE5 and PKG is also fostered under these circumstances and protected against breakdown, 58, 59 the sequestration of cGMP in these sites would result in higher cellular concentration of cGMP compared to the basal state and might provide a reservoir of cGMP for subsequent release, thereby altering efficiency derived from a subsequent small increase in the second messenger signal. 60 
Selective distribution of ligands
The characteristics that we have considered pertaining to selective partitioning of PDE5 inhibitors may be more common for other drugs than are generally appreciated. Results from studies of the tissue distribution of two compounds, chlordecone Potent inhibitors are reversibly bound to PDE5. The ratio of the rate of inhibitor dissociation (k off ) from the PDE5-inhibitor complex and the rate at which it is bound or rebound (k on ) is called the K D and reflects the affinity of the enzyme for the inhibitor. With very high affinity interactions, association with PDE5 is favored in this equilibrium so that much of the inhibitor rebinds quickly shortly after it dissociates from the enzyme and PDE5 activity is low as indicated by the white arrow. 61 Both are hydrophobic compounds that selectively accumulate in liver. [61] [62] [63] Evidence suggests that this selective hepatic sequestration most likely represents high affinity, but reversible, binding of the drug to glutathione and/or glutathione transferase, which are particularly abundant in liver compared to other tissues. Maximum binding of chlordecone in liver closely relates to concentration of glutathione in that tissue. Compounds that are chemically very similar to chlordecone or hexafluoroacetone (mirex and acetone, respectively) but lack high affinity for glutathione transferase do not selectively partition to the liver. 64 Therefore, in some instances, drugs that bind with high affinity to intracellular receptors that are particularly abundant in certain cell types preferentially accumulate in those cells; it would then be predicted that potent PDE5 inhibitors would reach higher concentrations in cells where PDE5 is particularly abundant.
Other model systems predict slow cellular removal of compounds that are tightly bound to intracellular proteins, thereby providing something like a 'memory device' for prolonged effects mediated by molecules even after extracellular concentration of the ligand has dropped substantially. 56, 65 This is supported by known characteristics of many high-affinity, slowly dissociating protein-ligand complexes. The exit of ribose from a dialysis bag is significantly slowed when the ribose-binding protein from Escherichia coli, which is involved in chemotactic responses, is present. 65 Similarly, dialysis of the regulatory subunit of cAMP-dependent protein kinase in complex with cAMP for 5 days does not remove cAMP from the dialysis bag. 57 25 and for the complex between hexoses (glucose and galactose) and a galactose-binding protein. 67 These events are not due to irreversibility of the interaction between the ligand and the protein because addition of a competing high-affinity ligand shows rapid exchange and displacement of the first ligand. Despite continual dissociation of ligands from their targets, those that bind with high affinity are likely to rapidly rebind, thereby prolonging the functional lifetimes of the complexes and presumably biological effects resulting from those complexes.
Other considerations
Many of the same mechanisms would be predicted to hasten onset of action of PDE5 inhibitors as well as to increase their maximum effect. These topics will be discussed elsewhere.
Concluding remarks
Two possible explanations for continued effects of PDE5 inhibitors in corpus cavernosum well after the inhibitor level in plasma has fallen to a subtherapeutic level are discussed herein. First, even if PDE5 inhibitor is efficiently cleared from the cell, effects resulting from PKG-mediated autophosphorylation and heterophosphorylation (phosphorylation of other cellular proteins) may be slow to reverse particularly if cGMP is elevated in the cells for an extended period of time. In particular, sustained autophosphorylation of PKG would keep the enzyme in a partially active state and also sensitize the enzyme to subsequent increases in cGMP, perhaps facilitating an erectile response despite a modest elevation of cGMP in response to a subsequent erotic stimulus. Second, the high affinity of PDE5 for inhibitors, the high concentration of PDE5 in tissues such as the corpus cavernosum and rebinding of inhibitors to PDE5 are predicted to prolong action beyond the time predicted from clearance of these medications from plasma. If PDE5 inhibitors are retained in the cell beyond the time of clearance from plasma, cGMP level and PKG activity may remain high in penile VSMC since PDE5 is the main cGMP-hydrolyzing PDE in this tissue, and it would continue to be blocked by the presence of the inhibitors. These considerations have important medical and financial implications for regimens used for treatment of ED, pulmonary arterial hypertension and other maladies associated with PDE5 action and warrant studies to address the basis for sustained effectiveness of PDE5 inhibitors beyond the time predicted from plasma clearance.
